Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Preferred Shares Issued (2023)

Historic Preferred Shares Issued for Contineum Therapeutics (CTNM) over the last 1 years, with Q3 2023 value amounting to $10.2 million.

  • Contineum Therapeutics' Preferred Shares Issued changed N/A to $10.2 million in Q3 2023 from the same period last year, while for Dec 2024 it was $10.2 million, marking a year-over-year change of. This contributed to the annual value of $60.1 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q3 2023, Contineum Therapeutics' Preferred Shares Issued is $10.2 million.
  • Contineum Therapeutics' 5-year Preferred Shares Issued high stood at $10.2 million for Q3 2023, and its period low was $10.2 million during Q3 2023.